Seres Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $789,000 | $0 | $0 | $7.1M | $144.9M |
| Research and development | $49.1M | $64.6M | $117.6M | $109.7M | $141.9M |
| Operating expenses | $94.8M | $121.3M | $195.1M | $179.9M | $209.4M |
| Operating income | -$94.0M | -$121.3M | -$195.1M | -$179.9M | -$64.5M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | $5.7M | $136,000 | -$113.7M | -$250.2M | -$65.6M |
| Balance Sheet | |||||
| Cash and equivalents | $45.8M | $30.8M | $128.0M | $163.0M | $180.0M |
| Current assets | $49.4M | $38.7M | $175.4M | $194.8M | $303.6M |
| Total assets | $138.2M | $139.8M | $358.6M | $348.8M | $354.9M |
| Current liabilities | $19.3M | $41.2M | $98.7M | $85.6M | $82.3M |
| Total liabilities | $94.0M | $126.0M | $403.5M | $338.0M | $223.4M |
| Stockholders' equity | $44.2M | $13.8M | -$44.9M | $10.8M | $131.5M |
| Cash Flow Statement | |||||
| Cash from operations | $1.1M | -$148.6M | -$117.4M | -$228.8M | $6.7M |
| Depreciation and amortization | $4.1M | $5.5M | $6.2M | $6.6M | $5.9M |
| Stock-based compensation | $10.8M | $21.0M | $34.1M | $25.5M | $20.2M |
| Capital expenditure | $252,000 | $380,000 | $8.0M | $9.8M | $9.6M |
| Free cash flow | $865,000 | -$149.0M | -$125.3M | -$238.6M | -$2.9M |
| Impairments | — | — | $0 | $0 | $0 |
Shares outstanding 9.6M · Free float 33.7%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.